Stock events for TriSalus Life Sciences, Inc. (TLSI)
In the past six months, several events have impacted TriSalus Life Sciences' (TLSI) stock price. The company reported its Fourth Quarter and Full-Year 2025 financial results on March 5, 2026, showing strong commercial performance with a 60% year-over-year increase in Q4 net sales and a 53% increase for the full year 2025, and also reported its Third Quarter 2025 earnings on November 13, 2025. In February 2026, TriSalus completed a public offering that raised $46 million in gross proceeds, which was more than twice oversubscribed. Wall Street Zen upgraded TriSalus Life Sciences from a "sell" to a "hold" rating on March 7, 2026, Canaccord Genuity Group reduced its target price from $12.00 to $7.00 while maintaining a "buy" rating, and Zacks Research upgraded the stock from a "strong sell" to a "hold" rating in December 2025. As of February 23, 2026, the share price was $4.99, representing a decline of 9.44% over the previous year, with the stock's 52-week range between $3.42 and $7.95.
Demand Seasonality affecting TriSalus Life Sciences, Inc.’s stock price
While there is no indication of natural demand seasonality for TriSalus Life Sciences' medical products, the company's revenue cadence is expected to be weighted towards the second half of 2026. This anticipated seasonality in revenue is attributed to upfront commercial investments and the timing of new product contributions, rather than inherent fluctuations in patient demand for their therapies.
Overview of TriSalus Life Sciences, Inc.’s business
TriSalus Life Sciences is an oncology-focused medical technology company dedicated to improving treatment outcomes for patients with solid tumors, particularly those in the liver and pancreas. The company operates within the Healthcare sector, specifically in the Biotechnology & Medical Research, Drug Delivery, and Medical Devices and Instruments industries. Its core business revolves around its proprietary Pressure-Enabled Drug Delivery (PEDD) platform, which aims to enhance the delivery of therapeutics to tumors while minimizing impact on healthy tissue. The company's major products include the TriNav Infusion System, the Pancreatic Retrograde Venous Infusion System, and Nelitolimod (SD-101). The company has expanded its product portfolio from two core commercial products at the start of 2025 to seven offerings entering 2026, including TriNav LV, TriGuide, TriNav FLX, and TriNav XP, with TriNav Advance anticipated in the first half of 2026.
TLSI’s Geographic footprint
TriSalus Life Sciences, Inc. has its corporate office located in Westminster, Colorado, United States. The available information does not specify a broader international geographic footprint for the company's operations or market reach beyond the U.S.
TLSI Corporate Image Assessment
In the past year, TriSalus Life Sciences has seen positive sentiment surrounding its strong financial performance, including exceeding its 2025 revenue guidance and robust Q4 revenue growth. The expansion of its PEDD platform and commercial footprint, along with a successful and oversubscribed public offering, have also contributed positively to its reputation. However, the company faces challenges that could impact its reputation, including a deeply negative net margin, poor financial strength, a high debt-to-equity ratio, and an Altman Z-Score indicating a potential risk of bankruptcy within the next two years. Additionally, the delay in releasing consolidated Phase 1 data for nelitolimod until the second half of 2026, aimed at creating a more complete data package for partners, and a reduction in internal development spending, could potentially defer near-term partnership progress or value realization.
Ownership
TriSalus Life Sciences, Inc. has 106 institutional owners and shareholders holding a total of 11,903,746 shares. Major institutional owners include Nantahala Capital Management, LLC, BlackRock, Inc., Vanguard Group Inc, AWM Investment Company, Inc., Gilder Gagnon Howe & Co Llc, Geode Capital Management, Llc, Alyeska Investment Group, L.P., and Morgan Stanley. Institutional ownership stands at approximately 22.88%, while insider ownership is around 7.47%. Shareholders have experienced substantial dilution in the past year, with total shares outstanding increasing by 96.1%.
